Bridges Investment Management Inc. Has $43.64 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Bridges Investment Management Inc. trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 267,830 shares of the company's stock after selling 9,031 shares during the period. Bridges Investment Management Inc. owned approximately 0.06% of Zoetis worth $43,638,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the third quarter valued at $31,000. First Personal Financial Services bought a new stake in Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the 3rd quarter valued at $33,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.

Zoetis Price Performance

Shares of NYSE ZTS traded down $2.94 during trading on Wednesday, reaching $166.96. The company had a trading volume of 3,666,660 shares, compared to its average volume of 3,280,356. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The business's 50 day moving average price is $166.53 and its 200-day moving average price is $177.06. The stock has a market cap of $74.76 billion, a PE ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis's payout ratio is 36.56%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ZTS. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target on the stock. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective for the company. Finally, Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.